117 related articles for article (PubMed ID: 2026487)
1. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Von Hoff DD; Green SJ; Neidhart JA; Fabian C; Budd T; Boyd JF; Osborne CK
Invest New Drugs; 1991 Feb; 9(1):87-8. PubMed ID: 2026487
[No Abstract] [Full Text] [Related]
2. A phase II study of alanosine in advanced large bowel carcinoma.
Rubin J; Hineman V; Moertel CG; Schutt AJ; Hahn RG
Am J Clin Oncol; 1983 Apr; 6(2):191-3. PubMed ID: 6829493
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
Creagan ET; Long HJ; Ahmann DL; Green SJ
Am J Clin Oncol; 1984 Oct; 7(5):543-4. PubMed ID: 6507375
[TBL] [Abstract][Full Text] [Related]
4. The treatment of acute leukemia with continuous infusion L-Alanosine.
Weick JK; Tranum BL; Morrison FS
Invest New Drugs; 1983; 1(3):249-51. PubMed ID: 6678874
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of L-alanosine (NSC 15353).
Goldsmith MA; Ohnuma T; Spigelman M; Greenspan EM; Holland JF
Cancer; 1983 Feb; 51(3):378-80. PubMed ID: 6821823
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.
Gockerman JP; Raney M; Logan T
Cancer Treat Rep; 1985 Sep; 69(9):1029-30. PubMed ID: 3861247
[No Abstract] [Full Text] [Related]
7. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
[No Abstract] [Full Text] [Related]
8. Phase I study of L-alanosine using a daily x 3 schedule.
Dosik GM; Stewart D; Valdivieso M; Burgess MA; Bodey GP
Cancer Treat Rep; 1982 Jan; 66(1):73-6. PubMed ID: 7053269
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of aclacinomycin-A (NSC-208734) in adenocarcinoma of the kidney.
Decker DA; Drelichman A; Opipari MI; Al-Sarraf M
Am J Clin Oncol; 1984 Oct; 7(5):527-8. PubMed ID: 6594927
[No Abstract] [Full Text] [Related]
10. Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.
Willson JK; Knuiman MW; Skeel RT; Wolter JM; Pandya KJ; Falkson G; Chang YC
Cancer Treat Rep; 1986 Oct; 70(10):1237-8. PubMed ID: 3530452
[No Abstract] [Full Text] [Related]
11. Alanosine (UCSD).
Yu J
Curr Opin Investig Drugs; 2001 Nov; 2(11):1623-30. PubMed ID: 11763167
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
[No Abstract] [Full Text] [Related]
14. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny NE; Gralla RJ
Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
[No Abstract] [Full Text] [Related]
15. Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Wander HE; Meyer D; Schuff-Werner P; Nagel GA
Onkologie; 1986 Aug; 9(4):236-8. PubMed ID: 3531951
[No Abstract] [Full Text] [Related]
16. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
[TBL] [Abstract][Full Text] [Related]
17. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Creagan ET; O'Connell MJ; Kovach JS
Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of 4'-epi-doxorubicin in advanced breast cancer.
Campora E; Nobile MT; Sertoli MR; Rosso R
Cancer Treat Rep; 1984 Oct; 68(10):1285-6. PubMed ID: 6597003
[No Abstract] [Full Text] [Related]
19. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
[No Abstract] [Full Text] [Related]
20. A clinical trial of mithramycin in the treatment of advanced malignant disease.
Baum M
Br J Cancer; 1968 Jun; 22(2):176-83. PubMed ID: 4873186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
